Genome Editing and Myocardial Development

Area of Science:

• Cardiovascular Genetics
• Developmental Biology
• Gene Editing Technologies

Background:

• Congenital heart disease (CHD) affects up to 1% of live births, with complex genetic origins involving over 400 genes crucial for myocardial development.
• Genetic mutations in intricate networks disrupt cardiovascular formation, leading to various heart abnormalities.

Approach:

• This review examines the anatomical and genetic timelines of myocardial development in humans and mice.
• It evaluates the potential of genome editing for treating syndromic, nonsyndromic, and familial CHD cases with identifiable mutations.
• The role of mouse models in replicating human CHD and testing gene correction strategies is discussed.

Key Points:

• Genome editing technologies present a viable future therapeutic strategy for CHD.
• Identifiable genetic mutations in various CHD forms indicate potential targets for gene therapy.
• Mouse models are instrumental in studying CHD pathogenesis and validating gene editing approaches.

Conclusions:

• CHD's strong genetic basis makes it a prime candidate for gene editing therapies.
• Advancements in genome editing technology hold promise for correcting causative mutations in CHD.
• Further research using established mouse models will facilitate the clinical translation of gene editing for CHD treatment.